IMMUNOLOGY AND INFLAMMATION Correction for “Neurotensin stimulates sortilin and mTOR in human microglia inhibitable by methoxyluteolin, a potential therapeutic target for autism,” by Arti B. Patel, Irene Tsilioni, Susan E. Leeman, and Theoharis C. Theoharides, which appears in issue 45, November 8, 2016, of Proc Natl Acad Sci USA (113:E7049–E7058; first published September 23, 2016; 10.1073/pnas.1604992113).
The authors note that their conflict of interest statement was omitted during publication. The authors declare the following: “T.C.T. has been awarded, under an agreement with Tufts University, the following patents: US 9,050,275 - Methods of Screening for and Treating Autism Spectrum Disorders and Compositions for Same and US 9,176,146 - Methods of Treating Autism Spectrum Disorders and Compositions for Same. A Provisional Patent Application was also filed by Tufts University as US 62/396,546 - Compositions and Methods of Autism Treatment. T.C.T. is also the Scientific Director of Algonot, LLC (Sarasota, FL) that has developed the flavonoid-containing trademarked dietary supplement NeuroProtek, for which Tufts receives royalties. No portion of the work described in this paper was funded by Algonot.”